<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198585</url>
  </required_header>
  <id_info>
    <org_study_id>Empire HF</org_study_id>
    <secondary_id>2017-001341-27</secondary_id>
    <nct_id>NCT03198585</nct_id>
  </id_info>
  <brief_title>Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction</brief_title>
  <acronym>Empire HF</acronym>
  <official_title>Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morten Schou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and
      during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and
      health-related quality of life in stable, symptomatic heart failure patients with reduced
      left ventricular ejection fraction.

      The primary hypothesis is that 3 months' treatment with Empagliflozin 10 mg a day will reduce
      the plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma concentrations of NT-proBNP</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in daily activity level measured by patient-worn accelerometers as change in the amount of daily average accelerometer units</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition assessed by DXA scan</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in extracellular volume assessed by Cr-51 EDTA</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma volume assessed by hematocrit and hemoglobin</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose metabolism assessed by oral glucose tolerance test</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ketone supply to the heart assessed by blood ketones</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function assessed by Cr-51 EDTA clearance</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in uric acid</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine albumin/creatinine ratio</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac biomarkers assessed by plasma concentrations of MR-proADM and MR-proANP</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac systolic and diastolic function including left ventricular global longitudinal strain assessed by transthoracic echocardiography at rest and during stress</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac hemodynamics during sub-maximal exercise assessed by right heart catheterization including pulmonary capillary wedge pressure to cardiac index ratio</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac hemodynamics during sub-maximal exercise assessed by right heart catheterization including left ventricular contractile reserve</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life assessed by the questionnaire KCCQ</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life assessed by the questionnaire EQ-5D-5L</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">189</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Empagliflozin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Capsule, once a day for 90 days</description>
    <arm_group_label>Empagliflozin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, once a day for 90 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Optimal Heart Failure Therapy in accordance with European and National Guidelines

          -  LVEF â‰¤ 0.40

          -  eGFR &gt; 30 ml/min/1.73 m2

          -  BMI &lt; 45 kg/m2

          -  NYHA class I-III

          -  Age &gt; 18 years

          -  If T2D - optimal treatment in accordance with European and National Guidelines

          -  If T2D - stable doses of antiglycemic treatment for 30 days

          -  If T2D - HbA1C 6.5-10%

        Exclusion Criteria:

          -  CRT-D/-P implanted &lt; 90 days

          -  Uncorrected severe valvular disease

          -  Non-compliance

          -  Use of metalozone

          -  NYHA IV

          -  Age &gt; 85 years

          -  Dementia

          -  Admission for HF &lt; 30 days

          -  Admission for hypoglycemia &lt; 12 month

          -  Known sustained VT

          -  Symptomatic hypotension and systolic BP &lt; 95 mmHg

          -  Unable to perform an exercise test

          -  Immobilization

          -  Pregnancy

          -  Participation in other medical trials

          -  Previous intolerance of Empagliflozin or excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Schou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev and Gentofte University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob E Moller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesper Jensen, MD</last_name>
    <phone>+45 38686258</phone>
    <email>jesper.jensen.06@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev and Gentofte University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper Jensen, MD</last_name>
      <phone>+45 38686258</phone>
      <email>jesper.jensen.06@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Morten Schou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesper Jensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massar Omar, MD</last_name>
      <phone>+45 608400609</phone>
      <email>massar.omar@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Jacob E Moller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massar Omar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Morten Schou</investigator_full_name>
    <investigator_title>MD, PhD, Consultant Cardiologist, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

